A major medical breakthrough has been achieved in the global fight against malaria, as the first-ever malaria treatment designed specifically for newborns and very young children has been approved for use. The drug, known as Coartem Baby (or Riamet Baby in some countries), is set to be introduced in several African nations within weeks, marking a critical step in reducing infant mortality due to malaria.
For decades, infants weighing less than 4.5kg (approximately 10 pounds) have lacked a dedicated treatment for malaria. Instead, they were administered adjusted versions of antimalarial medications developed for older children — a practice that raised significant safety concerns due to the risks of incorrect dosing.
Malaria remains one of the deadliest infectious diseases globally, particularly in sub-Saharan Africa. According to the latest figures from 2023, malaria was responsible for approximately 597,000 deaths worldwide, with a staggering 75% of those deaths occurring in children under the age of five. This alarming statistic highlights a critical need for safer and more effective malaria treatment options tailored specifically to the most vulnerable age group — newborns and infants.
Addressing a Dangerous Malaria Treatment Gap
Until now, clinicians were forced to use formulations intended for older children, risking overdoses in babies whose organs, especially the liver, are not yet developed enough to process higher doses safely. This left healthcare providers and families navigating a dangerous treatment gap that exposed infants to potential harm, and in some cases, insufficient care.
The new pediatric formulation has been developed by Novartis, a leading pharmaceutical company, in partnership with the Medicines for Malaria Venture (MMV), a Swiss-based nonprofit. The collaboration involved scientific, governmental, and philanthropic institutions, including support from the British, Swiss, and Dutch governments, the World Bank, and the Rockefeller Foundation.
What sets this development apart is not only its scientific significance but also its ethical framework. Novartis plans to make the drug available on a largely not-for-profit basis, a move that experts say will improve access in low-income regions where malaria is most deadly.
“For more than three decades, we have stayed the course in the fight against malaria,” said Vas Narasimhan, CEO of Novartis. “Together with our partners, we are proud to have developed the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve.”
Eight African countries were involved in the assessment and clinical trials of the new drug. These nations are expected to be among the first to receive access to Coartem Baby, enabling healthcare providers to deliver optimized and evidence-based malaria treatment to infants who previously had no safe therapeutic option.
Martin Fitchet, CEO of MMV, emphasized the importance of this step in the broader mission to eliminate malaria as a global health threat.
“Malaria is one of the world’s deadliest diseases, particularly among children. The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients,” Fitchet said. “It offers a valuable addition to the antimalarial toolbox.”
Medical experts and public health officials around the world are hailing this as a life-saving advancement. Dr. Marvelle Brown, associate professor at the University of Hertfordshire’s School of Health, Medicine and Life Sciences, called it a major breakthrough.
“Malaria treatment – The death rate for malarial infections, especially in sub-Saharan Africa, is extremely high — with over 76% of deaths occurring in children under five,” said Dr. Brown. “This is further complicated in babies born with conditions like sickle cell disease, which weakens the immune system. The new treatment, and the decision to offer it not-for-profit, represents a significant step toward health equity.”
As malaria treatment options continue to evolve, the approval of Coartem Baby offers new hope in the global campaign to eliminate malaria. The rollout of this infant-specific medication is expected to begin in Africa shortly, targeting the regions with the highest malaria burden.
Health experts believe this move will not only save thousands of lives each year but also pave the way for further innovations in pediatric care and infectious disease management. With continued partnerships, funding, and research, malaria’s deadly grip on the world’s youngest and most vulnerable can be loosened — and eventually, broken.
Source- BBC
